Analysts Issue Forecasts for Krystal Biotech FY2025 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Stock analysts at Chardan Capital dropped their FY2025 EPS estimates for shares of Krystal Biotech in a note issued to investors on Wednesday, May 7th. Chardan Capital analyst Y. Livshits now anticipates that the company will post earnings per share of $5.50 for the year, down from their prior estimate of $6.15. Chardan Capital currently has a “Buy” rating and a $219.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share.

Several other equities research analysts have also weighed in on the company. Jefferies Financial Group initiated coverage on Krystal Biotech in a report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 target price for the company. Guggenheim reduced their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Citigroup raised their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. Finally, HC Wainwright restated a “buy” rating and set a $240.00 price target on shares of Krystal Biotech in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $218.63.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS opened at $132.23 on Monday. The firm has a market cap of $3.82 billion, a price-to-earnings ratio of 44.22 and a beta of 0.79. The business’s 50-day simple moving average is $171.56 and its 200-day simple moving average is $170.01. Krystal Biotech has a 52 week low of $131.71 and a 52 week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million.

Institutional Investors Weigh In On Krystal Biotech

Institutional investors have recently bought and sold shares of the business. Norges Bank bought a new position in shares of Krystal Biotech during the 4th quarter worth about $34,391,000. Soleus Capital Management L.P. lifted its stake in Krystal Biotech by 65.2% during the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock worth $56,144,000 after purchasing an additional 141,400 shares during the period. GAMMA Investing LLC boosted its holdings in Krystal Biotech by 50,249.4% during the first quarter. GAMMA Investing LLC now owns 121,342 shares of the company’s stock valued at $21,878,000 after purchasing an additional 121,101 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Krystal Biotech in the 4th quarter valued at approximately $15,989,000. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Krystal Biotech by 16.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company’s stock worth $79,812,000 after buying an additional 71,200 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This trade represents a 1.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62% decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).